All In Biotech

Drug Trial Radar · NCT07734493

A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

A Phase 1b, Multicenter, Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Early Signs of Efficacy of Orally Administered LTX-001 As Monotherapy in Adult Participants With Acute Exacerbation of Schizophrenia

Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Aug 3, 2026

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Leal Therapeutics, IncIndustry
Sponsor type
Industry
First posted
Jul 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to learn whether the investigational drug LTX-001 is safe and well tolerated in adults with a diagnosis of schizophrenia who are having a recent worsening of their symptoms (an acute exacerbation). Additional questions it aims to answer are: * how does the amount of the study drug in the body change over time (pharmacokinetics) * how does the study drug affect the symptoms of schizophrenia * how do certain markers in the blood change after administration of LTX-001 (pharmacodynamics) Researchers will compare different dose levels of LTX-001 to an inactive product (placebo) to see what differences there are between the two treatments. After successfully screening for the study, participants will stay in a research unit for about five weeks and return one week later for a follow-up visit.

Conditions

  • Schizophrenia

Interventions

  • LTX-001 once dailyDrug

    LTX-001 40 mg and 60 mg administered as oral suspension

  • PlaceboDrug

    Oral suspension without LTX-001

  • LTX-001 twice dailyDrug

    LTX-001 30 mg and 60 mg administered as oral suspension

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability - Adverse EventsTime frame: Screening through Day 42
  2. Safety and Tolerability - Clinical Laboratory TestsTime frame: Screening through Day 42
  3. Safety and Tolerability - Electrocardiograms (ECG)Time frame: Screening through Day 42
  4. Safety and Tolerability - Physical and Neurological ExamsTime frame: Screening through Day 42
  5. Safety and Tolerability - SuicidalityTime frame: Screening through Day 42
  6. Safety and Tolerability - Extrapyramidal SymptomsTime frame: Screening through Day 42
  7. Vital signs - blood pressureTime frame: Screening through Day 42
  8. Vital Signs - heart rateTime frame: Screening through Day 42
  9. Vital Signs - respiratory rateTime frame: Screening through Day 42
  10. Vital Signs - body temperatureTime frame: Screening through Day 42
  11. Vital Signs - total body weightTime frame: Screening through Day 42
  12. Vital Signs - heightTime frame: Screening through Day 42
  13. Vital Signs - Body Mass Index (BMI)Time frame: Screening through Day 42
  14. Ocular evaluation - Best Corrected Visual Acuity (BCVA)Time frame: Screening through Day 42
  15. Ocular evaluation - dilated Color Fundus Photography (CFP)Time frame: Screening through Day 42
  16. Ocular evaluation - Fundus Autofluorescence (FAF)Time frame: Screening through Day 42
  17. Ocular evaluation - dilated Optical Coherence Tomography (OCT)Time frame: Screening through Day 42
  18. Ocular evaluation - slit lamp examinationTime frame: Screening through Day 42

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Pillar Clinical Research, LLC

    Little Rock, Arkansas · Recruiting

  • Collaborative Neuroscience Research, LLC

    Los Alamitos, California · Recruiting

  • University Clinical Research-DeLand, LLC d/b/a Accel Research Sites - DeLand Clinical Research Unit

    DeLand, Florida · Recruiting

  • Behavioral Clinical Research, Inc.

    Hollywood, Florida · Recruiting

  • CenExel Hollywood FL

    Hollywood, Florida · Recruiting

  • Innovative Clinical Research, Inc.

    Miami Lakes, Florida · Recruiting

  • CenExel iResearch, LLC

    Decatur, Georgia · Recruiting

  • CBH Health LLC., dba CenExel Gaithersburg MD

    Gaithersburg, Maryland · Recruiting

  • Hassman Research Institute, LLC

    Marlton, New Jersey · Recruiting

  • Pillar Clinical Research, LLC

    Richardson, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.